North America
In a Phase I study presented at AACR's annual meeting, 71 percent of patients who hadn't received a prior anti-HER2 ADC responded to the drug.
Personalized Neoantigen Vaccine Shows Feasibility but Limited Efficacy in MSS Colorectal Cancer
Premium
Researchers at AACR's annual meeting said they hope the vaccine will show stronger efficacy in patients with minimal residual disease.
The firm said it has begun to shift the few drugs made in Europe for the US to be manufactured domestically.
Octave Bioscience Gets NY State Certification for MS Test
With the certification from the NYS Clinical Laboratory Evaluation Program, the company said the test is now available throughout the US.
Merck KGaA Buying SpringWorks Therapeutics to Strengthen US Presence in Rare Tumors
SpringWorks sells two rare tumors drugs in the US and has two precision oncology drugs in early-stage development.
Apr 28, 2025
Apr 24, 2025
Apr 24, 2025
Apr 24, 2025